Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Net Cash Flow (2020 - 2025)

Bioventus' Net Cash Flow history spans 6 years, with the latest figure at $8.9 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 1465.85% year-over-year to $8.9 million; the TTM value through Dec 2025 reached $9.3 million, up 29.35%, while the annual FY2025 figure was $9.3 million, 29.35% up from the prior year.
  • Net Cash Flow reached $8.9 million in Q4 2025 per BVS's latest filing, down from $9.6 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $98.5 million in Q4 2022 to a low of -$108.4 million in Q4 2022.
  • Average Net Cash Flow over 5 years is -$1.7 million, with a median of $3.9 million recorded in 2024.
  • The largest YoY upside for Net Cash Flow was 1517.71% in 2022 against a maximum downside of 583.78% in 2022.
  • A 5-year view of Net Cash Flow shows it stood at -$31.9 million in 2021, then crashed by 240.43% to -$108.4 million in 2022, then surged by 96.4% to -$3.9 million in 2023, then skyrocketed by 114.62% to $571000.0 in 2024, then soared by 1465.85% to $8.9 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Net Cash Flow are $8.9 million (Q4 2025), $9.6 million (Q3 2025), and $9.9 million (Q2 2025).